Glaukos Corporation (NYSE:GKOS) Stock Has Average Price Target of $180.54

Shares of Glaukos Corporation (NYSE:GKOS) have been given a consensus recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $180.54.

GKOS has been the subject of several recent research reports. UBS Group started coverage on shares of Glaukos in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 price target for the company. Stifel Nicolaus lifted their price target on shares of Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. HC Wainwright boosted their price objective on shares of Glaukos from $168.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Needham & Company LLC raised their price objective on Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Citigroup lifted their price objective on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th.

Insider Activity

In other news, CFO Alex Thurman sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the transaction, the chief operating officer owned 72,588 shares in the company, valued at $13,046,967.12. This trade represents a 45.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 93,025 shares of company stock worth $16,550,006 in the last 90 days. 5.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Glaukos

Hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP acquired a new stake in Glaukos during the 2nd quarter worth about $28,000. CoreCap Advisors LLC bought a new stake in shares of Glaukos during the 3rd quarter valued at about $33,000. IFP Advisors Inc boosted its position in shares of Glaukos by 523.4% during the 2nd quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 246 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Glaukos by 25.4% during the third quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier’s stock worth $112,000 after purchasing an additional 138 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Durable Epioxa results support the corneal portfolio. Three-year Phase 3 extension data for Epioxa in keratoconus showed sustained efficacy and a favorable safety profile after a single treatment. The results strengthen the potential for a durable treatment benefit and may improve confidence in Glaukos’ corneal disease strategy. Glaukos’ Epioxa Shows Durable Three-Year Results in Keratoconus
• Positive Sentiment: Glaukos expanded its retina pipeline. The company entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, described as a first-in-class tri-specific biologic for retinal diseases. The deal broadens Glaukos’ growth opportunities beyond its existing surgical and corneal products, although the asset remains subject to development and regulatory risk. Glaukos and RevOpsis License Agreement
• Neutral Sentiment: Third-quarter results are scheduled for October 28. Investors will be watching the upcoming report for revenue growth, operating performance and updates on Epioxa and the retina pipeline. Glaukos’ most recently reported quarter showed revenue growth above 49% year over year and an adjusted loss narrower than analysts expected. Glaukos to Release Third Quarter 2026 Financial Results
• Negative Sentiment: Insider selling pressured sentiment. Reports indicated that insider transactions overshadowed the favorable Epioxa data, prompting concern among some investors about near-term valuation or management confidence. This selling-related pressure helps explain why the stock did not respond more positively to the clinical update. Glaukos Slips as Insider Selling Overshadows Positive Trial Data

Glaukos Stock Performance

NYSE GKOS opened at $160.83 on Tuesday. Glaukos has a fifty-two week low of $73.16 and a fifty-two week high of $191.62. The firm’s fifty day moving average price is $172.99 and its two-hundred day moving average price is $145.74. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The stock has a market cap of $9.49 billion, a PE ratio of -49.49 and a beta of 0.69.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period last year, the firm posted ($0.24) earnings per share. The business’s revenue for the quarter was up 49.6% on a year-over-year basis. On average, equities analysts expect that Glaukos will post -0.32 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products intended to preserve and restore vision. The company’s primary business is minimally invasive glaucoma surgery (MIGS), which is designed to reduce intraocular pressure and potentially lessen patients’ dependence on glaucoma medications.

Glaukos’ glaucoma portfolio includes the iStent, iStent inject and iStent infinite systems, which are used in procedures to improve the eye’s natural fluid outflow.